Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com
Investment analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research report issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Akari Therapeutics Price Performance Shares of Akari Therapeutics stock opened at $0.87 on Friday. The firm has a 50 day simple […]
More Stories
FAA Says It Will Commit $6 Billion to Air Traffic Control Modernization by Dec. 31
By Jacob Burg The Federal Aviation Administration (FAA) plans to commit $6 billion by the end of the year to...
Senate Passes $900 Billion Defense Bill, Sending It to Trump’s Desk
By Joseph Lord The U.S. Senate on Monday evening gave the green light to a $901 billion draft of the...
Europe Must Be Responsible for Its Own Security, Says EU Chief
By Victoria Friedman European Commission President Ursula von der Leyen said on Dec. 17 that the post-war era of peace...
Officials Release Enhanced Video Footage of Brown University Mass Shooting Suspect
By Jack Phillips Authorities released new video footage and a new timeline late Tuesday in connection with the fatal shooting...
The Fed Faces a Year-End Crossroad
By Louis Navellier Last Wednesday, the Federal Open Market Committee (FOMC) cut key interest rates 0.25% for the third time...
‘AI Can’t Climb a Utility Pole’—Experts Warn of ‘Silver Tsunami’ in US Utilities
By Mary Prenon Older employees have been the fastest-growing age group in the U.S. labor force for more than 20...